Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Fineline Cube Aug 25, 2026
Company Deals

Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321

Fineline Cube Aug 25, 2026
Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Fineline Cube Aug 25, 2026
Company Drug

Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease

Fineline Cube Aug 25, 2026
Company Drug

Antengene Clears Australian Regulatory Hurdles for Phase I ATTRACT Study of UCB‑Licensed ATG‑201

Fineline Cube Aug 25, 2026
Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment

Fineline Cube Nov 24, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance...

Company Deals

Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations

Fineline Cube Nov 24, 2023

Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly...

Company Drug

Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease

Fineline Cube Nov 24, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval...

Company Deals

True Health Secures Over RMB 100 Million in Series B+ Financing for Surgical Robot Development

Fineline Cube Nov 24, 2023

True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over...

Company Drug

MicuRx Pharmaceuticals Secures NMPA Approval for MRX-4 and Contezolid Combination Therapy

Fineline Cube Nov 24, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced that it has received clinical trial approval from...

Company Deals

Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China

Fineline Cube Nov 24, 2023

Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned...

Company Drug

C2 Pharma Secures C-DMF Approval for Pilocarpine Nitrate API

Fineline Cube Nov 24, 2023

Ireland-based C2 Pharma has announced the receipt of approval for a C-DMF (drug master file)...

Company Drug

SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...

Company Drug

Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study

Fineline Cube Nov 23, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab...

Company Drug

RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China

Fineline Cube Nov 23, 2023

China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...

Company Deals

Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio

Fineline Cube Nov 23, 2023

Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week,...

Company Drug Legal / IP

Bayer Halts Late-Stage Trial for Asundexian After Underperformance

Fineline Cube Nov 23, 2023

Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate...

Company Drug

Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China

Fineline Cube Nov 23, 2023

China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...

Company Deals

Venus Medtech Partners with Valgen Holding on DragonFly Valve System

Fineline Cube Nov 23, 2023

China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen...

Company Deals

Oculotronics Secures Pre-Series A Funding for Ophthalmic Surgical Robotics

Fineline Cube Nov 23, 2023

Oculotronics, a Guangzhou-based developer of ophthalmic surgical robots, has reportedly raised tens of millions of...

Company Drug

Sumitomo Pharma Receives Chinese Approval for Xenleta to Treat Pneumonia

Fineline Cube Nov 23, 2023

Japan-based Sumitomo Pharma Co., Ltd (OTCMKTS: DNPUF) has secured market approval in China for Xenleta...

Company Drug Medical Device

Gilead Announces Low-Carbon Bronchodilator Study for H1 2024

Fineline Cube Nov 23, 2023

Gilead Sciences Inc. (NASDAQ: GILD) has announced plans for a Phase III study in the...

Company Drug

Hunan Warrant Pharmaceutical’s ZG-001 Approved for Clinical Trial by NMPA

Fineline Cube Nov 22, 2023

Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical...

Company Drug

VivaVision Biotech Inc. Receives FDA Approval for VVN461 Phase II Clinical Trial

Fineline Cube Nov 22, 2023

China’s VivaVision Biotech Inc. has announced that it has received approval from the US Food...

Company Drug

AnHeart Therapeutics and Innovent Biologics File Taletrectinib for Marketing Approval in China

Fineline Cube Nov 22, 2023

China’s Center for Drug Evaluation (CDE) has indicated on its website that taletrectinib, an ROS1/NTRK...

Posts pagination

1 … 485 486 487 … 711

Recent updates

  • Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA
  • WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%
  • China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration
  • Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines
  • Hengrui’s NMPA Accepts NDA for HRG2010, a Novel Levodopa/Carbidopa Combination for Parkinson’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Legal / IP

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

Company

WuXi XDC H1 Revenue Surges 41.5% to RMB 3.7 Billion as ADC Backlog Jumps 50.4%

Hospital Policy / Regulatory

China’s NHC Issues Notice Deepening “Six Expansions” to Strengthen Family Doctor Contracted Services With AI Integration

Company Deals

Mirxes Signs Strategic MOU With GAIA Health to Expand Early Cancer Screening in the Philippines

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.